Altamira Therapeutics Ltd.
CYTOF
$0.07
$0.009916.47%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -2.17M | -2.17M | -- | -- | -2.97M |
| Total Depreciation and Amortization | 30.40K | 30.40K | -- | -- | 32.70K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 320.90K | 320.90K | -- | -- | 546.00K |
| Change in Net Operating Assets | 216.70K | 216.70K | -- | -- | -1.82M |
| Cash from Operations | -1.60M | -1.60M | -- | -- | -4.22M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 100.00 | 100.00 | -- | -- | -- |
| Other Investing Activities | 300.00 | 300.00 | -- | -- | 100.00 |
| Cash from Investing | 300.00 | 300.00 | -- | -- | 100.00 |
| Total Debt Issued | -- | -- | -- | -- | 1.37M |
| Total Debt Repaid | -36.50K | -36.50K | -- | -- | -86.10K |
| Issuance of Common Stock | 1.32M | 1.32M | -- | -- | 3.01M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -28.20K | -28.20K | -- | -- | -90.90K |
| Cash from Financing | 1.26M | 1.26M | -- | -- | 4.21M |
| Foreign Exchange rate Adjustments | 10.10K | 10.10K | -- | -- | 28.30K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -334.10K | -334.10K | -- | -- | 19.40K |
